Trendingnow
This Is How Tribune Publishing Wants to Stop a Gannett Bid

Photograph by Jewel SamadAFP/Getty Images
Add Fortune on Google for similar content.
About the Author
Add Fortune on Google for similar content.
Latest in Finance
Most Popular
© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
Newspaper publisher Tribune Publishing said its board had adopted a shareholder rights plan—popularly known as a “poison pill”—in a bid to thwart Gannett’s unsolicited takeover offer.
The rights will become exercisable after a group buys more than 20 percent of Tribune Publishing’s shares.
If the rights plan is triggered, Tribune shareholders will get the number of shares having a market value of two times the exercise price of the right, the company said.
Gannett, the owner of USA Today, made a takeover bid for Tribune last month at $12.25 per share in cash, valuing the publisher of the Chicago Tribune and the Los Angeles Times at about $815 million. Tribune rejected the offer last week.
“Our board is unanimous that Gannett will not succeed with its current tactics and low ball price,” Tribune Chief Executive Justin Dearborn said in a statement on Monday.
The tussle comes at a time when the print industry is grappling with declining circulation, shrinking advertising revenue and a shift toward digital content.
Gannett, which has expressed frustration over Tribune’s reluctance to engage in talks for a deal, urged the company’s shareholders last week to withhold their votes for board nominees during Tribune’s annual meeting on June 2.